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reactionAbstract Background: Drug safety is one of the hottest topics in daily medical practice, particu-
larly with regard to approving new medication or questioning the possibility of withdrawing a drug
from the market.
Aim: The aim of this review is to highlight the importance of the drug safety concept and its
impact on patients’ health.
Methods: A literature search was conducted using Pubmed, EMBASE, EBSCO and Medline
in the period between 1980 and 2013. The terms used in the search included ‘‘Drug Safety’’, ‘‘Med-
ication Safety’’, ‘‘Patient Safety’’, ‘‘Drug Interaction’’, ‘‘Drug Pharmacokinetic’’, and ‘‘Adverse
Drug Reaction’’. All retrieved abstracts were evaluated within the context of the review objectives.
The full texts of the selected articles were included in this review. Studies in non-English language
were excluded in this review.
Results: Since the early days of the past century, many acts, laws, or amendments have been cre-
ated to make sure that approved drugs are ﬁrst safe and then effective. Furthermore, these regula-
tions are continuing to change to make sure that these drugs have a positive beneﬁt–risk balance.
Personalized medicine should be considered when medications are given to patients because the
pharmacokinetic process inside the body varies from patient to patient and from one speciﬁc disease
state to another. However, adverse drug reactions can be minimized if more precautions are taken
by healthcare professionals, especially including the patient as one pillar of the therapeutic plan and
providing more patient counseling, which will improve drug safety.
Conclusion: The drug safety concept has earned a lot of attention during the past decade due to
the fact it plays a major role in patients’ health. Recent laws stress this concept should be included
406 T.M. Alshammariin the process of new medications’ approval and continued conduct of post-marketing drug evalu-
ations. Beneﬁt–risk assessment should be considered by all health care professionals when they need
to give speciﬁc drugs to speciﬁc groups of patients. Therefore, more care should be given to some
patients, such as pregnant women, children and the elderly, since they are considered vulnerable
populations.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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The concept of drug safety, also called ‘‘Medication Safety’’, is
not new, especially in the developed countries in the ﬁeld of
health. For instance, we ﬁnd in the United States of America
(USA) an experience for more than a century in the ﬁeld of
the safety of medications, and the use of these drugs led to cre-
ation of new acts or changes to the existing ones. For example,
in October 1937, the use of the antibiotic sulfanilamide caused
the death of more than 100 people in the USA. These deaths
were not due to the active ingredient itself; rather, they were
caused by the addition of diethylene glycol (DEG), the excip-
ient used as a solvent for the active drug. DEG was supposed
to be inert, with no therapeutic beneﬁts; however, it was the
toxic substance that led to those fatal side effects. The com-
pany claimed they did not foresee these side effects, which
was true, as they did not commit animal studies before they
marketed the drug. Because of this incident, the U.S. Food
and Drug Administration (FDA) approved an act to ensure
the safety of any drug by conducting non-clinical and clinical
studies before the drugs are marketed for public use (Geiling
and Cannon, 1938; Young, 1984; Wax, 1995).
Of course, the problems arising from drugs and their side
effects did not stop occurring. A severe worldwide crisis was
initiated by the use of the drug thalidomide, which was used
as an antiemetic agent for pregnant women in many countries.
In the early 1960s, the use of thalidomide during the ﬁrst tri-
mester of pregnancy led to teratogenic effects manifested by
the birth of infants with severe deformities known as ‘‘Phoco-
melia’’. Babies would be born lacking extremities (hands and
legs) or with only very short ones. Many infants died because
of this ‘‘medication’’ as well. Overall, more than 10,000 chil-
dren in 46 countries were victims of thalidomide. It is impor-
tant to mention that this drug was not authorized orapproved for use in the United States because of some
concerns that arose during non-clinical studies (animal studies)
due to the existence of cases of deformities on animal embryos.
Note that those animal studies were conducted according to
the act that was initiated following the sulfanilamide incident
in the USA; therefore the public was protected and avoided
from this crisis (Ito et al., 2011; Kim and Scialli, 2011;
Martinez-Frias, 2012).
Up until now, there are drugs that could be taken off the
market or withdrawn due to safety issues concerning their rela-
tion with the emergence of serious side effects, such as the
recent withdrawal of the anti-diabetic agent rosiglitazone
(Avandia) from the global market as a result of its relation-
ship with the incidence of heart attacks. Therefore, we ﬁnd the
concept of drug safety a very important and comprehensive
concept that is considered a priority with regard to the use
of medications. Actually, this concept can be considered an
integrated science in itself that involves many other scientiﬁc
aspects, such as the side effects of drugs, the quality of medica-
tions, medical errors in the use of drugs, lack of efﬁcacy of
drugs, and counterfeit drugs (Psaty and Furberg, 2007a,b;
Hiatt et al., 2013). In Saudi Arabia, there is a need to educate
and enhance the knowledge of healthcare professionals regard-
ing the concept of drug safety since many studies that have
been conducted in Saudi Arabia found that there is a lack of
culture of drug safety in Saudi Arabia among all levels of
healthcare professionals (Aljadhey et al., 2014; Khan, 2013;
Mahmoud et al., 2014).
2. Methods
A search of several databases (Pubmed, EMBASE,
EBSCO and Medline) was carried out in the period between
1980 and 2013. Several terms were used in the search, including
Drug Safety Concept and its Importance 407‘‘Drug Safety’’, ‘‘Medication Safety’’, ‘‘Patient Safety’’, ‘‘Drug
Interaction’’, ‘‘Drug Pharmacokinetic’’, and ‘‘Adverse Drug
Reaction’’. All retrieved abstracts were evaluated within the
context of the review objectives and only studies in English
language were included in this review. The full texts of the
selected articles were included in this review.
3. Drug safety facts
All drugs have side effects, but the extent of their impact and
severity varies from mild (such as mild itching or mild head-
ache) to severe (such as severe rash, damage to vital organs,
primarily the liver and kidneys, and possibly even death). Most
of the side effects are predictable and mentioned in the leaﬂets
for each drug. However, the serious problem is that some of
the drugs’ side effects are not previously known or have not
been noticed, and the real risk here is whether they would exert
a severe deleterious impact on the patients who are using them.
Among the factors that may increase the severity of the side
effects, the type of medications and the type of patients using
them are the most important (Gholami and Shalviri, 1999;
Hilmer et al., 2007).
Some drugs may not cause serious symptoms, such as cer-
tain types of antibiotics; other medications may cause serious
symptoms, such as certain cancer drugs, anti-diabetic medica-
tions, medications to control elevated blood lipids, and many
others. Nonetheless, serious adverse reactions can arise from
widely used and well-known medications. For example, many
people might believe that paracetamol, which is sold as
Panadol, Fevadol, Tylenol and under other trade names,
is very safe and would not cause serious side effects. However,
this drug can induce dangerous side effects at high doses, par-
ticularly ones affecting the liver. What makes this worse is that
the drug is found in many combinations used for cold and ﬂu,
and the patient might be unaware of this and take extra doses,
leading to a direct liver injury (Larson, 2007; Chun et al., 2009;
Bunchorntavakul and Reddy, 2013).
4. Speciﬁc patient populations and drug safety
The type of patients using medications is a very important fac-
tor in considering drugs’ side effects. People vary in their
responses to medications according to their age (Crooks and
Stevenson, 1981). In addition, responses to drugs vary between
males and females due to the physiological differences between
genders (Xie et al., 1997; Beierle et al., 1999; Franconi et al.,
2007). In addition, there are patient groups that need greater
attention and care when using medications, such as pregnant
women, the elderly, and children (Sannerstedt et al., 1996).
4.1. Pregnant and lactating women
Each phase of pregnancy, which lasts nine months, is consid-
ered important and critical during the use of any medication.
Pregnancy is divided into three major trimesters: the ﬁrst tri-
mester (the ﬁrst three months), the second trimester (the sec-
ond three months), and the third trimester (the last three
months of pregnancy). As mentioned earlier, all these trimes-
ters are important periods; therefore, a pregnant woman must
not take any medication without consulting a specialist (a phy-
sician or a pharmacist) about the safety of the medication as itmay affect the formation of the fetus, as was the case with the
use of thalidomide, as mentioned above.
The danger of effects of drugs is not limited to taking drugs
during pregnancy: deleterious effects on the fetus may be expe-
rienced even if a medication is taken within a short time period
before pregnancy (perhaps several weeks) (Dai et al., 1989;
Schaefer et al., 2010). For example, the drug isotretinoin
(Roaccutane), used for the treatment of acne, is considered
one of the most dangerous medications during pregnancy as
it has teratogenic effects on the fetus; therefore it is contraindi-
cated during pregnancy. Thus, with the use of this drug, it is
important to consult and advise women not to become preg-
nant even after cessation of drug use. This could occur by
informing them of the matter and advising them to consider
the possibility of using contraception. Also, during the period
of lactation, mothers should consult professionals before use
of any medication because some medications can be excreted
in breast milk, which may have a negative impact on the
infant. These warnings should not be applied only to chemi-
cally synthesized drugs, but should also be considered while
using any herbal medicines or anything that is taken or used
as a medicine (Dumont and Black, 2013).4.2. Children (pediatrics)
The second category to consider, which is no less important
than the category of pregnant women, is children. It is crucial
to take extreme caution when using any medications for
children as many medications are divided depending on age
group – some medications are contraindicated in patients less
than 18 years or less than 12 years old, and also some medica-
tions are contraindicated for use in children less than two years
old. The reasons include mostly the lack of scientiﬁc studies
and clinical trials needed to evaluate the safety of these medi-
cations in each age group separately. In addition, children’s
vital organs are not mature, and thus exposure to certain med-
ications may lead to toxic side effects as the body is mostly
unable to fully metabolize or excrete the drugs. This would
lead to the presence of active compounds in the body for an
extended period of time as well as an increase in their levels
in the body, inducing toxic effects (Ryan et al., 2008;
Vassilev et al., 2010; Adefurin et al., 2011; Yang and So,
2013). This can usually be avoided by adjusting the dose but,
as mentioned earlier, the lack of clinical studies to evaluate
the pharmacokinetic proﬁle of these drugs makes it difﬁcult
to adjust the dose; thus many drugs are not recommended
for use in certain age groups.
Furthermore, it is crucial to use medications in this age
group in the exact dose prescribed or recommended, as devia-
tion from that dose may lead to severe side effects if increased
or would render the drug ineffective, imposing a danger on
children as the disease is not being treated effectively. What
also contributes to this problem is that a drug can be formu-
lated in different dosage forms. For example, a medication
can be formulated in the form of syrups, tablets, capsules,
and suppositories. This may have an impact as each dosage
form has a different pharmacokinetic proﬁle, especially as
regards their absorption rate – e.g., syrups have faster absorp-
tion than tablets or suppositories – and thus the dose should be
taken as prescribed by the physician and reviewed by the
pharmacist (Levy, 1964; Vogt et al., 1994).
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measuring tool with liquid preparations that are administered
orally to ensure exact and correct doses at every use. Preferred
measuring tools would be divided into milliliters. For example,
plastic syringes are excellent choices for administering syrups
to children. They are better than measuring caps as they are
easier to handle and can provide precise and accurate dosing
(Madlon-Kay and Mosch, 2000; Sobhani et al., 2008; Ryu
and Lee, 2012; Spiegel et al., 2013). If a medication is only
available in the form of tablets or capsules, it is preferable to
consult a pharmacist about the proper way to use the drug
and how it should be administered to children. Tablets are usu-
ally advised to be taken with ample quantities of juice or water.
Also, if tablets will be taken with food, it is important to know
if the tablet could be subject to drug–food interaction and the
pharmacist should provide the proper advice.
Aspirin, or ‘‘acetylsalicylic acid’’, which is widely used as an
analgesic and antipyretic, is one of the drugs that are safely
used in adult groups but contraindicated in children, as it
could lead to a severe adverse effect known as ‘‘Reye’s Syn-
drome’’. Thus, a safer alternative to be given to children would
be paracetamol and ibuprofen in the correct adjusted dose and
based on weight as well (Boucher and Beaulac-Baillargeon,
2006; Selves et al., 2013).
It is important to consider the weight of the child while pre-
scribing medications and their doses, as the dosages of most
drugs used for children are calculated based on the weight of
the child. The storage of pediatric medications is important
as well. Every dispensed drug is accompanied by instructions
for proper storage, such as the suitable recommended temper-
ature for that purpose. There are some important instructions
that may be overlooked by parents, such as making sure the
medications have not expired. Also families need to be very
careful with medications in general and be aware that they
must be kept out of reach of children to prevent accidental
ingestion, which could be fatal in many situations.
4.3. Old people (geriatrics)
The geriatric group is considered to be most vulnerable to the
effect of medications and so it is very important to consider
their health status before prescribing any medication, for sev-
eral reasons. The physiological functions of many body organs
decline with age, especially important organs such as the liver
and kidneys. Older people may also suffer from dementia or
‘‘impaired memory’’ and so forget to take their medications
(Wright and Warpula, 2004; Arlt et al., 2008; Toba, 2011;
Dhikav et al., 2013; Haider et al., 2013). Older people can suf-
fer from many chronic illnesses, such as high blood pressure,
diabetes, and high blood cholesterol and lipids, possibly neces-
sitating the chronic use of multiple medications, which may
conﬂict with each other – what is known as drug–drug interac-
tion. Depending on the type of interaction between drugs, it is
possible that the drug level in the plasma would increase too
much, leading to toxicity and severe adverse reactions. The
opposite can be true as well – the drug may be in low plasma
concentrations, exposing the patient to dangers and complica-
tions of the illness that was supposed to be controlled by that
drug.(Jankel and Speedie, 1990; Ansari, 2010; Hines and
Murphy, 2011) Geriatric patients might take more than 16 dif-
ferent medications daily, which makes the chance of the inci-dence of drug–drug interaction very high, especially if they
then take OTC medications without consulting their doctor
or pharmacist. In addition, older patients tend to try and use
herbal extracts, for which there are not enough scientiﬁc data
about components which may be dangerous or which could
interact with their prescribed medications. This could worsen
the conditions they suffer from, such as chronic, heart, liver
and kidney diseases. Also, certain types of food may interact
with the prescribed medications, with the same outcomes as
those mentioned regarding drug–drug interactions, but with
different mechanisms (Fugh-Berman and Ernst, 2001;
Schmidt and Dalhoff, 2002; Fujita, 2004; Heuberger, 2012).
The incidence of side effects can be easily avoided by apply-
ing certain preventive measures on the part of the patient. One
of these measures is full awareness and knowledge about the
medications used, and this can be achieved by reading the leaf-
let included in the package of the drug, which usually contains
all the necessary information about the drug. The patient can
also consult the pharmacist or the doctor for better explana-
tions if needed. As healthcare professionals are usually very
busy, it is recommended that the patient should prepare his/
her inquiries in advance and write them down, and then pres-
ent them to their doctor or pharmacist. The patient should also
bring all his/her medications with him/her to all appointments
with either the doctor or the pharmacist in order that the pro-
fessional can avoid dispensing drugs that may interact with
each other. In addition, it is preferable that old people utilize
the assistance available in pharmacies to organize and arrange
the administration of their medications correctly. Also it is
necessary for every patient to be honest and frank when pro-
viding information to their health care professionals. For
example, many patients may hide that they drink alcohol.
Alcohol affects metabolism greatly and thus may lead to tox-
icity when taken with drugs prescribed in the normal dosage
regimen. Last, the patient must understand and learn the
proper method and use of medications to avoid misuse of
the drug, which may lead to either side effects or lack of efﬁ-
cacy and beneﬁt. One may use the previously mentioned meth-
ods of prevention for any patient, whether the elderly or the
others.
It is important to point out that the concepts of drug safety
and the proper use of medications are not limited to a certain
class of patient or medication users, but are applied to any per-
son who uses a medication.
5. Drug safety and drug–drug and food–drug interaction
Different medications can interact with each other and cause
what is known as drug interactions, which can occur with
almost all drugs. Such interactions could occur at any stage
while the drug is present within the body. These interactions
could either reduce or increase the effect of other drugs, or
could produce a different, new effect. Drug interactions can
occur in any pharmacokinetic (PK) process, including absorp-
tion, distribution, metabolism, and excretion. All these PK
processes are important and it is therefore crucial that patients
should consult a physician or pharmacist about the possible
interactions that may occur between drugs and with certain
foods to avoid undesirable effects (Karch and Lasagna, 1975).
There are many occasions when drugs may interact with
each other in absorption – one such has been observed with
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interacts with other medications by decreasing their absorption
and thus reducing their effect as their concentrations in the
plasma are lowered.(Bays and Dujovne, 1998) Also, iron-con-
taining products which are used for treatment of certain types
of anemia can decrease absorption of other drugs, and so it is
recommended these drugs are used at least two hours apart. In
addition, some types of food may interact with certain medica-
tions. For example, calcium-containing foods such as milk and
cheese can chelate and form large complex molecules with the
antibiotic group tetracyclines, preventing their absorption in
the gastrointestinal tract (GIT) and rendering them ineffective
in combating infection (Schmidt and Dalhoff, 2002).
The second phase of pharmacokinetics in which medica-
tions may interact with each other is the distribution phase.
Many drugs are bound to proteins in the plasma, such as albu-
mins and globulins. Protein-bound drugs are not effective and
the free plasma concentration of a drug is the active one.
Bound and unbound forms of a drug exist in balance with each
other and portions of the bound drug are released from their
proteins as the free unbound drugs get involved in the rest of
the pharmacokinetic processes, including excretion. What
can happen is that some drugs may displace other drugs from
their proteins, increasing their free unbound concentration in
the plasma – leading to adverse effects and signs of toxicity
under a normal dosage regimen. For example, the anticoagu-
lant agent warfarin (Coumadin) is a highly protein-bound
drug (97%), meaning that only 3% of the dose is active for
biological effects. The widely used antipyretic agent aspirin
can displace warfarin from plasma proteins, leading to serious
bleeding. Thus, it is very important to be vigilant about this
fact, responding by either providing a different antipyretic
agent that does not displace warfarin or by adjusting the
warfarin dose (lowering the dose) to prevent serious side
effects (Zibaeenezhad et al., 2004; Ageno et al., 2012;
Pranckeviciene et al., 2013).
The metabolism is one of the most important pharmacoki-
netic processes and can have great involvement in drug–drug
or drug–food interactions. The liver produces many enzymes
that are mainly responsible for deactivating xenobiotic agents,
including the medications we use. Many drugs can alter liver
enzymes by either increasing their expression or lowering their
expression and production. The best known drugs that induce
liver enzymes are the antibiotic drug rifampicin (Rifampin)
and the antiepileptic agent phenytoin (Dilantin) (Lehtinen
et al., 2013; Yamashita et al., 2013). Well-known and widely
used drugs that are liver enzyme inhibitors include the antibi-
otics erythromycin (Ery-Tab) and azithromycin (Zithro-
max), and the antifungal ketoconazol (Nizoral). A
controversial drug–drug interaction related to induction of
microsomal liver enzymes is that observed with the co-admin-
istration of antibiotics and contraceptives. Antibiotics reduce
the level of the contraceptives and thus they may fail to prevent
pregnancy (Shah et al., 2009; Smith et al., 2012; Quinney et al.,
2013).
The last stage of pharmacokinetics at which drug interac-
tions may occur is the excretion phase. This could happen when
the transporters or the mechanisms by which a drug is excreted
are the same for another drug that is concomitantly adminis-
tered, leading to a delay in the excretion of one of the drugs
and increasing its concentration in the body, which can result
in toxicity and side effects. An example of such interaction is thatobserved when aspirin and the anticancer drug methotrexate
(Trexall) are co-administered (Tracy et al., 1992; Bannwarth
et al., 1996; Iqbal et al., 1998; Vakily et al., 2005).
Food–drug interactions can frequently happen and they
can be very serious. For example, tyramine-rich food such as
cheese, red meat, and excessive amounts of chocolate can inter-
act with the speciﬁc antidepressant group of monoamine oxi-
dase inhibitor (MAO-I) drugs, leading to the possibility of
inducing a dangerous hypertensive crisis (McCabe, 1986;
Livingston and Livingston, 1996; Tipton, 1997; Corti and
Taegtmeyer, 2012). Some foods are well known for their effect
in inducing or inhibiting liver enzymes. Grapefruit juice is a
potent inhibitor of CYP450 enzymes that are important in
metabolizing certain antihyperlipidemic agents, such as ator-
vastatin (Lipitor), lovastatin (Mevacor), and simvastatin
(Zocor), and hence increase their levels in the body, leading
to side effects and toxicity (Fukazawa et al., 2004; Karch,
2004; Ando et al., 2005; Reddy et al., 2011). On the other
hand, the herbal extract St. John’s wort, which is used as an
antidepressant agent, is a potent liver enzyme inducer that
would lower the concentrations of drugs such as digoxin, lead-
ing to reduction in its efﬁcacy and worsening of the congestive
heart failure disease which digoxin is used for. In addition,
many calcium and iron-containing foods can impair the
absorption of other drugs, as I have described above with spe-
ciﬁc examples (Johne et al., 1999; Markowitz and DeVane,
2001; Mueller et al., 2004).
Every patient or medication user must ensure they are
aware of all necessary information regarding those drugs, as
well as the possibility of interactions with other drugs or cer-
tain food types, through consulting the pharmacist or physi-
cian. This should be done to avoid any potential risks or
adverse effects, as well as for proper control of their disease
or illness. Groups that are at extreme risk and exposure to
those drug interactions include:
 Patients who use multiple medications, especially six or
more medications.
 Elderly patients (geriatrics).
 Patients with multiple chronic diseases and illnesses,
such as heart disease, diabetes, or hyperlipidemia.
 Patients who use medications that could produce serious
side effects and have narrow therapeutic index, such as
the anticoagulant agent warfarin, the antiepileptic phe-
nytoin, and certain heart failure medications including
digoxin.
6. Minimizing drug side effects
As previously stated, each drug has its side effects; however, it
is possible to avoid these side effects by using the drug in the
proper way, and by following the instructions included in the
drug leaﬂet or provided by the pharmacist or the physician.
Knowing the necessary information about a medicine is con-
sidered the ﬁrst step in avoiding side effects. For example,
when a patient knows that a drug should not be taken at a cer-
tain time or with another drug, he/she can avoid the incidence
of inappropriate drug interactions and gain the full beneﬁt
from his/her medications. Similarly, when a patient knows that
he/she should not take a particular drug with food or certain
types of it, again his/her medications will be efﬁcacious, with
minimal adverse reactions. When a pregnant woman knows
410 T.M. Alshammarishe must not take any medication before consulting the doctor
or pharmacist, then she will avoid deleterious effects that may
be induced by teratogenic medications and will continue with a
safe pregnancy.
Some questions and points considered during patient coun-
seling that are usually raised by healthcare professionals include:
s Should the patient avoid taking a certain medication
with other medications?
s Should the patient avoid taking it with certain food or
beverages?
s What are the expected side effects of the drugs?
s The medical team should encourage the patient to men-
tion over-the-counter (OTC) medications bought
directly from the pharmacy without a prescription,
such as cough and cold medications including paracet-
amol or aspirin.
s The medical team should encourage the patient to
bring all his/her medications when he/she goes to see
his/her physician.
s The medical team should counsel the patient about all
herbal medications that he/she uses, as well as vitamins
and dietary supplements.
s The patient should feel comfortable in asking the phy-
sician or the pharmacist how his/her drugs work to
produce their medical effects.
s Patients should be informed about the proper use of
the medications; how many/much, how many times a
day, and for how long.
s Patients should be informed regarding the proper uses
of injectable medications such as insulin injections.
s The medical team should provide all information required
by patients regarding the proper storage of medications, as
there are many drugs that are affected by exposure to light
or storage at inappropriate temperatures.
s The patient should ask his/her physician or pharmacist
about the active ingredients in OTC medications, as
some may contain paracetamol and usingmultiplemedica-
tions may lead to the ingestion of extra doses, resulting in
liver damage.
7. Conclusion
Drug safety is the main aspect of medical therapy that can play a
major role in deciding which drug should be given to a patient.
Also, considering the concept of beneﬁt–risk balance, we found
that drugs with a high risk proﬁle should be avoided unless
needed. Drug safety has gone through different stages from the
last century and till now and there have been several tragedies
that we should learn from to protect our patients. All patients
should be protected; nevertheless, speciﬁc groups of patients
should be given more care, such as pregnant women, children,
and the elderly, since they are considered vulnerable populations.
Drugs can react with other drugs or foods used on a daily basis
and speciﬁc precautions are required to avoid these simple but
dangerous interactions. However, the risks from medications
could be minimized through patient education about drug safety
and openness with the patient, allowing him/her to ask questions
related to their disease or medications. A good relationship
between the medical team and the patient is one of the most
important determinants for drug safety.Conﬂict of interest
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